Clinical Trials Logo

Adenocarcinoma of the Prostate clinical trials

View clinical trials related to Adenocarcinoma of the Prostate.

Filter by:

NCT ID: NCT01228084 Completed - Clinical trials for Adenocarcinoma of the Prostate

Sulforaphane in Treating Patients With Recurrent Prostate Cancer

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sulforaphane works in treating patients with recurrent prostate cancer. Sulforaphane may prevent or slow the growth of certain cancers.

NCT ID: NCT01117935 Completed - Clinical trials for Adenocarcinoma of the Prostate

Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer

Start date: May 30, 2010
Phase: N/A
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy, such as intensity-modulated radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This clinical trial studies intensity-modulated external beam radiation therapy in treating patients with prostate cancer.

NCT ID: NCT01094288 Completed - Clinical trials for Advanced Solid Tumors

A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

Start date: August 17, 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of alisertib in combination with docetaxel as a treatment for participants with advanced solid tumors, including castration-resistant prostate cancer, who were deemed by the investigator to be medically appropriate candidates for docetaxel therapy.

NCT ID: NCT01054079 Completed - Clinical trials for Adenocarcinoma of the Prostate

Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Start date: September 2011
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment

NCT ID: NCT01050842 Completed - Prostate Cancer Clinical Trials

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Start date: February 2010
Phase: Early Phase 1
Study type: Interventional

RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Selective estrogen receptor modulators, such as raloxifene, may work together with bicalutamide to stop the growth of prostate cancer. PURPOSE: This clinical trial studies giving bicalutamide and raloxifene together in treating patients with metastatic or hormone-refractory prostate cancer.

NCT ID: NCT01028885 Completed - Prostate Cancer Clinical Trials

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

Start date: June 2009
Phase: Phase 1
Study type: Interventional

This is a prospective clinical trial examining the use of MRI to measure internal organ motion and any resulting changes in the target volume (shape and location) during a course of post-operative radiation therapy for prostate cancer. The goal is to better understand and characterize these physiologic variations so that they can be accounted for during the treatment planning process. The ultimate longer-term clinical goal here is to provide a form of adaptive radiation therapy in the future, such that if major changes are seen over an 8-week course of radiation therapy in our study. This may argue for hypofractionating those patients who are most likely to have major shifts over time.

NCT ID: NCT01023061 Completed - Clinical trials for Adenocarcinoma of the Prostate

Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer

Start date: March 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy works in treating patients with localized or locally advanced prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, leuprolide acetate, and goserelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving abiraterone acetate and leuprolide acetate or goserelin before or together with radiation therapy may be an effective treatment for prostate cancer.

NCT ID: NCT00915122 Completed - Clinical trials for Adenocarcinoma of the Prostate

Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate

Start date: November 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the feasibility and late toxicity of dose escalated radiation therapy to the pelvic lymph nodes and prostate and seminal vesicles in the treatment of high risk prostate cancer. All eligible patients with high risk prostate cancer who are going to have primary radiation therapy to the pelvic lymph nodes and prostate seminal vesicles with or without concurrent hormonal therapy will be approached regarding study entry.

NCT ID: NCT00666666 Completed - Clinical trials for Adenocarcinoma of the Prostate

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Start date: July 2009
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving gossypol together with androgen ablation therapy works in treating patients with newly diagnosed metastatic prostate cancer. Gossypol may stop the growth of tumor cells by blocking blood flow to the tumor. Androgens can cause the growth of prostate tumor cells. Luteinizing hormone-releasing hormone agonists and drugs, such as bicalutamide, may lessen the amount of androgens made by the body. Giving gossypol together with androgen ablation therapy may be an effective treatment for prostate cancer

NCT ID: NCT00608920 Completed - Clinical trials for Adenocarcinoma of the Prostate

Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping

SPECT
Start date: March 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the planning of radiation treatment of prostate cancer patient can be made more precise by comparing currently planning techniques to an imaging technique called SPECT.